Wedbush Securities Inc. Purchases 98 Shares of Axon Enterprise, Inc $AXON

Wedbush Securities Inc. lifted its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 3.9% in the second quarter, Holdings Channel reports. The institutional investor owned 2,612 shares of the biotechnology company’s stock after acquiring an additional 98 shares during the period. Wedbush Securities Inc.’s holdings in Axon Enterprise were worth $2,163,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of AXON. Jennison Associates LLC raised its stake in Axon Enterprise by 23,203.7% in the 1st quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company’s stock worth $322,961,000 after purchasing an additional 611,418 shares in the last quarter. Nuveen LLC acquired a new position in shares of Axon Enterprise during the 1st quarter worth approximately $264,796,000. McElhenny Sheffield Capital Management LLC bought a new position in shares of Axon Enterprise during the second quarter worth approximately $255,833,000. Westfield Capital Management Co. LP raised its position in shares of Axon Enterprise by 29.8% in the first quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock valued at $487,977,000 after buying an additional 212,931 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Axon Enterprise by 2.2% in the first quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company’s stock valued at $4,540,005,000 after buying an additional 185,571 shares during the period. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have commented on AXON shares. Weiss Ratings restated a “hold (c)” rating on shares of Axon Enterprise in a research note on Wednesday, October 8th. Zacks Research cut Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 2nd. JPMorgan Chase & Co. raised their price target on Axon Enterprise from $730.00 to $850.00 and gave the stock an “overweight” rating in a research report on Thursday, July 17th. Wall Street Zen cut shares of Axon Enterprise from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Cowen reiterated a “buy” rating on shares of Axon Enterprise in a research note on Wednesday. Fifteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $810.71.

Axon Enterprise Trading Up 2.6%

Shares of AXON opened at $602.51 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. Axon Enterprise, Inc has a 52-week low of $469.24 and a 52-week high of $885.91. The firm has a market cap of $47.54 billion, a price-to-earnings ratio of 148.77, a PEG ratio of 29.49 and a beta of 1.45. The business’s fifty day moving average is $719.61 and its 200-day moving average is $736.04.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $1.17 earnings per share for the quarter, missing the consensus estimate of $1.63 by ($0.46). Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The business had revenue of $710.64 million during the quarter, compared to analyst estimates of $704.83 million. During the same period last year, the business earned $1.45 earnings per share. The business’s quarterly revenue was up 30.6% compared to the same quarter last year. Axon Enterprise has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CAO Jennifer H. Mak sold 77 shares of the firm’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $760.00, for a total value of $58,520.00. Following the sale, the chief accounting officer directly owned 15,003 shares in the company, valued at approximately $11,402,280. This trade represents a 0.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Patrick W. Smith sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 7th. The stock was sold at an average price of $713.74, for a total transaction of $7,137,400.00. Following the transaction, the chief executive officer owned 3,033,982 shares of the company’s stock, valued at approximately $2,165,474,312.68. This represents a 0.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 59,932 shares of company stock worth $45,115,616 in the last quarter. Corporate insiders own 4.40% of the company’s stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.